Rep. Val T. Hoyle Sells GSK PLC Sponsored ADR (NYSE:GSK) Stock

Key Points

• Representative Val T. Hoyle sold shares of GSK PLC Sponsored ADR (NYSE:GSK) valued between $1,001 and $15,000 on September 23rd, as disclosed in a filing on October 10th.
• After recent earnings results, GSK reported an EPS of $1.23 for the last quarter, exceeding the consensus estimate, with a year-over-year revenue increase of 1.3%.
• GSK has recently cut its dividend payout to $0.4206, representing an annualized yield of 3.9% and a dividend payout ratio of 78.24%.

Representative Val T. Hoyle (D-Oregon) recently sold shares of GSK PLC Sponsored ADR NYSE: GSK. In a filing disclosed on October 10th, the Representative disclosed that they had sold between $1,001 and $15,000 in GSK stock on September 23rd. The trade occurred in the Representative's "FIDELITY ROLLOVER IRA" account.

Representative Val T. Hoyle also recently made the following trade(s):

• Sold $1,001 - $15,000 in shares of Marriott International NASDAQ: MAR on 9/23/2025.
• Sold $1,001 - $15,000 in shares of Transdigm Group NYSE: TDG on 9/23/2025.
• Sold $1,001 - $15,000 in shares of H&R Block NYSE: HRB on 9/23/2025.
• Sold $1,001 - $15,000 in shares of NIKE NYSE: NKE on 9/23/2025.
• Sold $1,001 - $15,000 in shares of Bank of New York Mellon NYSE: BK on 9/23/2025.
• Sold $1,001 - $15,000 in shares of Cisco Systems NASDAQ: CSCO on 9/23/2025.
• Sold $1,001 - $15,000 in shares of Capital One Financial NYSE: COF on 9/23/2025.
• Sold $1,001 - $15,000 in shares of Pentair NYSE: PNR on 9/23/2025.
• Sold $1,001 - $15,000 in shares of Heico NYSE: HEI.A on 9/23/2025.
• Sold $1,001 - $15,000 in shares of Target NYSE: TGT on 9/23/2025.

GSK Trading Up 0.2%

Shares of NYSE GSK opened at $43.53 on Friday. The company has a market cap of $88.55 billion, a price-to-earnings ratio of 20.15, a price-to-earnings-growth ratio of 1.96 and a beta of 0.53. GSK PLC Sponsored ADR has a 12-month low of $31.72 and a 12-month high of $45.59. The company has a current ratio of 0.87, a quick ratio of 0.57 and a debt-to-equity ratio of 1.07. The stock's 50 day simple moving average is $40.33 and its 200 day simple moving average is $38.85.

GSK (NYSE:GSK - Get Free Report) last announced its quarterly earnings results on Wednesday, July 30th. The pharmaceutical company reported $1.23 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.12 by $0.11. The business had revenue of $10.64 billion for the quarter, compared to the consensus estimate of $7.92 billion. GSK had a return on equity of 49.22% and a net margin of 10.81%.The business's revenue was up 1.3% on a year-over-year basis. During the same quarter last year, the business posted $0.43 EPS. GSK has set its FY 2025 guidance at 4.590-4.590 EPS. Equities research analysts expect that GSK PLC Sponsored ADR will post 4.14 EPS for the current year.

GSK Cuts Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, October 9th. Investors of record on Friday, August 15th were issued a $0.4206 dividend. The ex-dividend date of this dividend was Friday, August 15th. This represents a $1.68 annualized dividend and a dividend yield of 3.9%. GSK's dividend payout ratio (DPR) is 78.24%.

Hedge Funds Weigh In On GSK

Hedge funds have recently modified their holdings of the company. Twin Peaks Wealth Advisors LLC acquired a new position in shares of GSK during the 2nd quarter valued at $25,000. HHM Wealth Advisors LLC grew its holdings in shares of GSK by 222.2% in the 1st quarter. HHM Wealth Advisors LLC now owns 667 shares of the pharmaceutical company's stock worth $26,000 after acquiring an additional 460 shares during the last quarter. Costello Asset Management INC acquired a new stake in shares of GSK during the first quarter worth $31,000. Richardson Financial Services Inc. lifted its holdings in shares of GSK by 127.9% during the first quarter. Richardson Financial Services Inc. now owns 841 shares of the pharmaceutical company's stock valued at $33,000 after purchasing an additional 472 shares during the last quarter. Finally, SOA Wealth Advisors LLC. boosted its position in shares of GSK by 252.1% in the 2nd quarter. SOA Wealth Advisors LLC. now owns 845 shares of the pharmaceutical company's stock valued at $32,000 after purchasing an additional 605 shares during the period. 15.74% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

GSK has been the topic of several recent analyst reports. Wall Street Zen raised GSK from a "buy" rating to a "strong-buy" rating in a research note on Friday, September 5th. Weiss Ratings reaffirmed a "hold (c)" rating on shares of GSK in a research note on Wednesday. Seven research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Reduce" and an average target price of $37.38.

About Representative Hoyle

Val Hoyle (Democratic Party) is a member of the U.S. House, representing Oregon's 4th Congressional District. She assumed office on January 3, 2023. Her current term ends on January 3, 2027. Hoyle (Democratic Party) is running for re-election to the U.S. House to represent Oregon's 4th Congressional District. She declared candidacy for the 2026 election. Val Hoyle was born in California and lives in Springfield, Oregon. Hoyle graduated from Merrimack High School. She earned a B.A. in political science from Emmanuel College in 1992. Her career experience includes working as a director at United Way of Lane County, a policy fellow at Wayne Morse Center for Law and Politics, and a commissioner at the Oregon Bureau of Labor and Industries. Hoyle has also worked in domestic and international sales, as well as manufacturing distribution.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.